U.S., EU, Japan Accept Regulatory Submissions For Review Of Pfizer's Lorlatinib

Pfizer Inc. (PFE) said that the U.S. Food and Drug Administration or FDA has accepted and granted Priority Review to the company's New Drug Application for lorlatinib.

from RTT - Biotech http://ift.tt/2BSN62n
via IFTTT